Table 1 Patient characteristics stratified by treatment group
Characteristic | Overall (n = 134) | Standard-dose (n = 66) | High-dose (n = 68) | P-value |
|---|---|---|---|---|
Age, years | 0.010 | |||
Median (IQR) | 67.0 (62.0–74.0) | 70.0 (63.0–76.0) | 65.5 (61.0–69.2) | |
Range | 40.0–86.0 | 40.0–86.0 | 47.0–79.0 | |
Sex, n (%) | 0.51 | |||
Female | 20 (14.9) | 8 (12.1) | 12 (17.6) | |
Male | 114 (85.1) | 58 (87.9) | 56 (82.4) | |
Tumor location, n (%) | 0.68 | |||
Cervical esophagus | 6 (4.5) | 3 (4.5) | 3 (4.4) | |
Upper thoracic esophagus | 18 (13.4) | 9 (13.6) | 9 (13.2) | |
Middle thoracic esophagus | 67 (50.0) | 36 (54.5) | 31 (45.6) | |
Lower thoracic esophagus | 43 (32.1) | 18 (27.3) | 25 (36.8) | |
Tumor length, mm | 0.62 | |||
Median (IQR) | 45.0 (30.0–70.0) | 45.0 (30.0–77.5) | 45.0 (30.0–70.0) | |
Range | 4.0–180.0 | 5.0–180.0 | 4.0–150.0 | |
Clinical depth of invasion, n (%) | 0.51 | |||
EP/LPM | 33 (24.6) | 19 (28.8) | 14 (20.6) | |
MM/SM1 | 32 (23.9) | 14 (21.2) | 18 (26.5) | |
SM2 | 69 (51.5) | 33 (50.0) | 36 (52.9) | |
Pretreatment staging combined with EUS | ||||
No | 100 (74.6) | 39 (59.1) | 61 (89.7) | < 0.001 |
Yes | 34 (25.4) | 27 (40.9) | 7 (10.3) | |
Radiotherapy technique, n (%) | 0.007 | |||
3D-CRT | 118 (88.1) | 53 (80.3) | 65 (95.6) | |
IMRT/VMAT | 16 (11.9) | 13 (19.7) | 3 (4.4) | |
Elective nodal irradiation, n (%) | < 0.001 | |||
No | 68 (50.7) | 9 (13.6) | 59 (86.8) | |
Yes | 66 (49.3) | 57 (86.4) | 9 (13.2) | |
Chemotherapy, n (%) | 1.000 | |||
Cisplatin + 5-fluorouracil | 124 (92.5) | 61 (92.4) | 63 (92.6) | |
Others | 10 (7.5) | 5 (7.6) | 5 (7.4) | |